Clinical Trials Therapeutics Disease Modeling Targeted Therapy AI in Healthcare DNA-Encoded Chemical Libraries Protein Structure Prediction Vaccines Disease Treatment Cancer Research Viral Inactivation Protein-Based Therapies Protein-based Drugs Synthetic Proteins Therapeutic Design Antibiotics Molecular Biology Anti-Aging Treatments Chemical Reactions Breakthroughs Therapeutic Options Aduhelm Efficacy Therapeutic Response Vaccine Research Regulatory Approval Life-saving Drugs Structural Biology Oncology Clinical Guidelines Photopharmacology Protein Interactions AI in Medicine Antiparasitic Drugs Vaccine Targets Antiviral Drugs Inflammatory Diseases Combination Therapy FDA Regulations Targeted Therapies Monoclonal Antibodies Nanotechnology Gout Treatment Protein Targets Testing Methods Ophthalmic Solutions Phase 3 Trials Disease Mechanisms New Treatments Clinical Testing Protein Biology Cancer Treatment Biotechnology
The debt-funded purchase adds late-stage URAT1 inhibitor pozdeutinurad with 2026 Phase 3 results expected to guide filings.
